Rapid and sensitive LC-MS/MS method for determination of megestrol acetate in human plasma: Application to a human pharmacokinetic study

Biomedical Chromatography

Volumn 27, Issue 4, 2013, Pages 409-415

  Seo, Ji Hyung ^a   Park, Ji Sun ^a   Jo, Min Ho ^a   Park, Mi Sun ^a   Ryu, Ju Hee ^a   Cho, Young Wuk ^a   Shim, Wang Sup ^a   Noh, Gyu Jeong ^b   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

Human plasma; LC MS MS; Megestrol acetate; Pharmacokinetics; Validation

Indexed keywords

ELECTROSPRAY IONIZATION; HYDROSPHERE; LIQUID CHROMATOGRAPHY; PLASMA (HUMAN); POSITIVE IONS; SIGNAL TO NOISE RATIO;

HUMAN PHARMACOKINETICS; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; LOWER LIMITS OF QUANTITATIONS; MEGESTROL ACETATE; PHARMACOKINETIC STUDIES; SIMPLE++; VALIDATION;

PHARMACOKINETICS;

MEGESTROL ACETATE; TOLBUTAMIDE;

ACCURACY; ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; NORMAL HUMAN; SIGNAL NOISE RATIO; SINGLE DRUG DOSE; STANDARD; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY;

EID: 84874931973     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2807     Document Type: Article

References (18)

1. Adlercreutz H, Eriksen PB and Christensen MS. Plasma concentrations of megestrol acetate and medroxyprogesterone acetate after single oral administration to healthy subjects. Journal of Pharmaceutical and Biomedical Analysis 1983; 1: 153-162.
2. Dawson NA and McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. The Journal of Urology 1995; 153: 1946-1947.
3. Deschamps B, Musaji N and Gillespie JA. Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. International Journal of Nanomedicine 2009; 4: 185-192.
4. Farinha A, Bica A and Tavares P. Improved bioavailability of a micronized megestrol acetate tablet formulation in humans. Drug Development and Industrial Pharmacy 2000; 26: 567-570.
5. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R and Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology 2004; 92: 10-14.
6. Gaver RC, Movahhed HS, Farmen RH and Pittman KA. Liquid chromatographic procedure for the quantitative analysis of megestrol acetate in human plasma. Journal of Pharmaceutical Sciences 1985; 74: 664-667.
7. Hooijerink H, Van Bennekom EO and Nielen MWF. Screening for gestagens in kidney fat using accelerated solvent extraction and liquid chromatography electrospray tandem mass spectrometry. Analytica Chimica Acta 2003; 483: 51-59.
8. Joos PE and Van Ryckeqhem M. Liquid chromatography-tandem mass spectrometry of some anabolic steroids. Analytical Chemistry 1999; 71: 4701-4710.
9. KFDA. Bioanalytical Method Validation. Korea Food and Drug Administration, 2003. Available from: http://ezdrug.kfda.go.kr/kfda2
10. Malone EM, Elliot CT, Kennedy DG and Regan L. Development of a rapid method for the analysis of synthetic growth promoters in bovine muscle using liquid chromatography tandem mass spectrometry. Analytica Chimica Acta 2009; 637: 112-120.
11. Mortensen SK and Pedersen M. Confirmatory analysis of acetylgestagens in plasma using liquid chromatography-tandem mass spectrometry. Analytica Chimica Acta 2007; 586: 217-222.
12. Parnes HL, Abrams JS, Tchekmedyian NS, Tait N and Aisner J. A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer. Breast Cancer Research and Treatment 1991; 18: 171-177.
13. Taylor RL, Grebe SK and Singh RJ. Quantitative, highly sensitive liquid chromatography-tandem mass spectrometry method for detection of synthetic corticosteroids. Clinical Chemistry 2004; 50: 2345-2352.
14. US DHHS, FDA and CDER. Guidance for Industry: Waiver of in Vivo Bioavilability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. US Department of Health and Human Service, Food and Drug Administration, and Center for Drug Evaluation and Research, 2000.
15. US DHHS, FDA and CDER. Guidance for Industry: Bionalytical Method Validation. US Department of Health and Human Service, Food and Drug Administration, and Center for Drug Evaluation and Research, 2001.
16. Van de Waterbeemd H, Testa B, Mannhold R, Kubinyl H and Folkers G. Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavilability. Wiley-VCH: Chichester, 2008: 33.
17. Von Roenn JH, Armstrong D, Kotler DP, Cohn DL, Klimas NG, Tchekmedyian NS, Cone L, Brennan PJ, Weitzman SA. Megestrol acetate in patients with AIDS-related cachexia. Annals of Internal Medicine 1994; 121: 393-393.
18. Yeh SS and Schuster MW. Megestrol acetate in cachexia and anorexia. International Journal of Nanomedicine 2006; 1: 411-416.